thalidomide has been researched along with Thrombophilia in 15 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)." | 9.14 | Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010) |
| "Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma." | 8.84 | Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 7.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)." | 5.14 | Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010) |
| " We report the results of a prospective randomized trial of 62 newly diagnosed MM patients tested at baseline for hypercoagulability and treated with intensive chemotherapy with or without thalidomide in a randomized fashion." | 5.10 | Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M, 2002) |
| "Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma." | 4.84 | Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008) |
| " Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)." | 3.79 | Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 3.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Thrombosis was not associated with inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1." | 2.94 | Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. ( Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C, 2020) |
| "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications." | 2.50 | [Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cornell, RF | 1 |
| Goldhaber, SZ | 1 |
| Engelhardt, BG | 1 |
| Moslehi, J | 1 |
| Jagasia, M | 1 |
| Harrell, S | 1 |
| Rubinstein, SM | 1 |
| Hall, R | 1 |
| Wyatt, H | 1 |
| Piazza, G | 1 |
| Bradbury, CA | 1 |
| Craig, Z | 1 |
| Cook, G | 1 |
| Pawlyn, C | 1 |
| Cairns, DA | 1 |
| Hockaday, A | 1 |
| Paterson, A | 1 |
| Jenner, MW | 1 |
| Jones, JR | 1 |
| Drayson, MT | 1 |
| Owen, RG | 1 |
| Kaiser, MF | 1 |
| Gregory, WM | 1 |
| Davies, FE | 1 |
| Child, JA | 1 |
| Morgan, GJ | 1 |
| Jackson, GH | 1 |
| Storrar, NPF | 1 |
| Mathur, A | 1 |
| Johnson, PRE | 1 |
| Roddie, PH | 1 |
| Zitomersky, NL | 1 |
| Levine, AE | 1 |
| Atkinson, BJ | 1 |
| Harney, KM | 1 |
| Verhave, M | 1 |
| Bousvaros, A | 1 |
| Lightdale, JR | 1 |
| Trenor, CC | 1 |
| Ordi-Ros, J | 1 |
| Cosiglio, FJ | 1 |
| Kovacs, MJ | 1 |
| Davies, GA | 1 |
| Chapman, JA | 1 |
| Bahlis, N | 1 |
| Voralia, M | 1 |
| Roy, J | 1 |
| Kouroukis, CT | 1 |
| Chen, C | 1 |
| Belch, A | 1 |
| Reece, D | 1 |
| Zhu, L | 1 |
| Meyer, RM | 1 |
| Shepherd, L | 1 |
| Stewart, KA | 1 |
| Gieseler, F | 1 |
| Talamo, GP | 1 |
| Ibrahim, S | 1 |
| Claxton, D | 1 |
| Tricot, GJ | 1 |
| Fink, LM | 1 |
| Zangari, M | 3 |
| Cini, M | 1 |
| Zamagni, E | 1 |
| Valdré, L | 1 |
| Palareti, G | 1 |
| Patriarca, F | 1 |
| Tacchetti, P | 1 |
| Legnani, C | 1 |
| Catalano, L | 1 |
| Masini, L | 1 |
| Tosi, P | 1 |
| Gozzetti, A | 1 |
| Cavo, M | 1 |
| Rodeghiero, F | 1 |
| Elice, F | 2 |
| Kaushal, V | 1 |
| Kaushal, GP | 1 |
| Melkaveri, SN | 1 |
| Mehta, P | 2 |
| Potenza, L | 1 |
| Luppi, M | 1 |
| Morselli, M | 1 |
| Saviola, A | 1 |
| Ferrari, A | 1 |
| Riva, G | 1 |
| Longo, G | 1 |
| Marietta, M | 1 |
| Torelli, G | 1 |
| Fink, L | 2 |
| Tricot, G | 2 |
| Pitini, V | 1 |
| Arrigo, C | 1 |
| Aloi, G | 1 |
| Azzarello, D | 1 |
| La Gattuta, G | 1 |
| Saghafifar, F | 1 |
| Anaissie, E | 1 |
| Badros, A | 1 |
| Desikan, R | 1 |
| Fassas, A | 1 |
| Morris, C | 1 |
| Toor, A | 1 |
| Whitfield, D | 1 |
| Siegel, E | 1 |
| Barlogie, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma[NCT00049673] | Phase 3 | 332 participants (Actual) | Interventional | 2002-10-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Thrombophilia
| Article | Year |
|---|---|
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End | 2014 |
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myelom | 2008 |
Thrombosis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines | 2007 |
5 trials available for thalidomide and Thrombophilia
| Article | Year |
|---|---|
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm | 2020 |
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De | 2020 |
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Combined Modality The | 2015 |
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Topics: Activated Protein C Resistance; Adult; Aged; Anticoagulants; Case-Control Studies; Dexamethasone; Fa | 2010 |
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood C | 2002 |
7 other studies available for thalidomide and Thrombophilia
| Article | Year |
|---|---|
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dise | 2019 |
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli | 2013 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che | 2009 |
Thalidomide and thrombosis.
Topics: Humans; Incidence; Neoplasms; Thalidomide; Thrombophilia; Thrombosis | 2003 |
Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology.
Topics: Angiogenesis Inhibitors; Apoptosis; Caspase 3; Caspases; Cell Size; Cell Survival; Cells, Cultured; | 2004 |
Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making.
Topics: Aged; Decision Making; Female; Humans; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as T | 2004 |
Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Topics: Angiogenesis Inhibitors; Collateral Circulation; Combined Modality Therapy; Diabetes Mellitus, Type | 2002 |